Drug Type Bispecific antibody |
Synonyms TJ-L1T6 |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 29 May 2021 |